Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT00559455
- Locations
- 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of
Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis
- Conditions
- Bacterial Vaginosis
- Interventions
- Drug: Lactoserum (Dermacyd Femina®)
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2009-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 122
- Registration Number
- NCT00556179
- Locations
- 🇧🇷
Sanofi-aventis, São Paulo, Brazil
Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2007-11-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT00553020
Glycemic Optimization Treatment Study
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 5062
- Registration Number
- NCT00552370
Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects
- Conditions
- InfluenzaMyxovirus Infection
- Interventions
- Biological: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)Biological: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)Biological: Split, Inactivated, Trivalent Influenza Vaccine (High-dose)Biological: Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2098
- Registration Number
- NCT00551031
Satisfaction and Compliance of Risedronate in PMO
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2007-10-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT00549965
- Locations
- 🇰🇷
Sanofi-Aventis, Daegu, Korea, Republic of
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 172
- Registration Number
- NCT00549939
- Locations
- 🇷🇺
Sanofi-Aventis Aministrative Office, Moscow, Russian Federation
🇹🇷Sanofi-Aventis Administrative Office, Istanbul, Turkey
Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma
- Conditions
- LymphomaNon-Hodgkin
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 39
- Registration Number
- NCT00549185
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
POWER Point of Care Effect on Satisfaction of Treatment
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2433
- Registration Number
- NCT00549068
Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol
- Conditions
- HypertensionDiabetes Mellitus Type 2
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2007-10-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT00549133
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey